BRCA1: mechanisms of inactivation and implications for management of patients.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  The Lancet

• Publication date

  2002-09-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0140-6736(02)11087-7PMID 12383682
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Survival and tumor characteristics of German hereditary breast cancer patients

  2004cited by this paper
• Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

  2002cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.

  2002cited by this paper
• Frequency of BRCA1 dysfunction in ovarian cancer.

  2002cited by this paper
• Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

  2002cited by this paper
• Current management of menopausal symptoms in cancer patients.

  2002cited by this paper
• The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

  2002cited by this paper
• Modifiers of risk of hereditary breast and ovarian cancer

  2002cited by this paper
• Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.

  2002cited by this paper
• Model‐based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center

  2002cited by this paper
• Effect of BRCA mutations on the length of survival in epithelial ovarian tumors.

  2002cited by this paper
• Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

  2001cited by this paper
• Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas

  2001cited by this paper
• The Royal Marsden Hospital (RMH) Trial

  2001cited by this paper
• The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in australian Ashkenazi Jews

  2001cited by this paper
• Uncovering BRCA1-regulated signalling pathways by microarray-based expression profiling.

  2001cited by this paper
• Gene-expression profiles in hereditary breast cancer.

  2001cited by this paper
• Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer

  2001cited by this paper
• Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice

  2001cited by this paper
• Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

  2001cited by this paper
• Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

  2001cited by this paper
• Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.

  2001cited by this paper
• The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews

  2001cited by this paper
• Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.

  2001cited by this paper
• Occult Carcinoma in Prophylactic Oophorectomy Specimens: Prevalence and Association With BRCA Germline Mutation Status

  2001cited by this paper
• New complexities for BRCA1 and BRCA2.

  2001cited by this paper
• Breast cancer screening for high-risk women: too little, too late?

  2001cited by this paper
• BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents

  2001cited by this paper
• Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.

  2001cited by this paper
• Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.

  2001cited by this paper
• Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.

  2000cited by this paper
• Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer.

  2000cited by this paper
• Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.

  2000cited by this paper
• The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.

  2000cited by this paper
• Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

  2000cited by this paper
• Long-term follow-up of the Stockholm screening study on ovarian cancer.

  2000cited by this paper
• Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2.

  1999cited by this paper
• Genetic counselling for hereditary breast cancer.

  1999cited by this paper
• Psychological and social determinants of women's decisions to undergo genetic counseling and testing for breast cancer

  1999cited by this paper
• Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?

  1999cited by this paper
• Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.

  1999cited by this paper
• Brca1 controls homology-directed DNA repair.

  1999cited by this paper
• Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.

  1998cited by this paper
• Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.

  1998cited by this paper
• Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells

  1998cited by this paper
• BRCA-associated breast cancer in young women.

  1998cited by this paper
• BRCA1 is associated with the centrosome during mitosis.

  1998cited by this paper
• Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.

  1998cited by this paper
• Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.

  1998cited by this paper
• BRCA1 testing--advances and retreats.

  1998cited by this paper
• Oral Contraceptives and the Risk of Hereditary Ovarian Cancer

  1998cited by this paper
• A superfamily of conserved domains in DNA damage‐ responsive cell cycle checkpoint proteins

  1997cited by this paper
• Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage.

  1997cited by this paper
• Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?

  1997cited by this paper
• BRCA1 mutations and survival in women with ovarian cancer.

  1997cited by this paper
• Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.

  1997cited by this paper
• Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families

  1997cited by this paper
• BRCA1 mutations and survival in women with ovarian cancer.

  1997cited by this paper
• Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases

  1997cited by this paper
• Statement of the American Society of Clinical Oncology : Genetic testing for cancer susceptibility. Commentaries

  1996cited by this paper
• Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.

  1996cited by this paper
• Transcriptional activation by BRCA1

  1996cited by this paper
• BRCA1 protein products ... Functional motifs...

  1996cited by this paper
• Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.

  1996cited by this paper
• Evidence for a transcriptional activation function of BRCA1 C-terminal region.

  1996cited by this paper
• …Functional motifs…

  1996cited by this paper
• Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.

  1995cited by this paper
• The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues

  1995cited by this paper
• Ovarian cancer: screening, treatment, and followup.

  1995cited by this paper
• Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression

  1995cited by this paper
• Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families

  1994cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1994cited by this paper
• BRCA1 mutations in primary breast and ovarian carcinomas.

  1994cited by this paper
• Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center.

  1993cited by this paper
• Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the gilda radner familial ovarian cancer registry

  1993cited by this paper
• Linkage of early-onset familial breast cancer to chromosome 17q21.

  1990cited by this paper
• Proceedings of the American Society of Clinical Oncology

  1982cited by this paper

• MiR-409-3p/Rab10/BRCA1 axis inhibits malignant transformation of endometrial carcinoma

  2025cites this paper
• DGKζ depletion attenuates BRCA1-mediated DNA repair mechanism.

  2025cites this paper
• Blood molybdenum level as a marker of cancer risk on BRCA1 carriers

  2024cites this paper
• Network-based analysis identifies key regulatory transcription factors involved in skin aging.

  2023cites this paper
• Use of Arabidopsis thaliana as a model to understand specific carcinogenic events: Comparison of the molecular machinery associated with cancer-hallmarks in plants and humans.

  2023cites this paper
• Expression of BRCA1 by immunohistochemistry and its association with ER, PR, Her2neu status in infiltrative ductal carcinoma of breast

  2023cites this paper
• Habitat Analysis of Breast Cancer-Enhanced MRI Reflects BRCA1 Mutation Determined by Immunohistochemistry

  2022cites this paper
• Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis

  2022cites this paper
• Robust analysis of cancer heterogeneity for high‐dimensional data

  2022cites this paper
• A BRCA1 Splice Site Variant Responsible for Familial Ovarian Cancer in a Han-Chinese Family

  2022cites this paper
• Single nucleotide polymorphisms in breast cancer susceptibility gene 1 are associated with susceptibility to lung cancer.

  2021cites this paper
• Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing

  2021cites this paper
• The 1,000 Genomes Project has established the most detailed catalogue of mutations in the human genome, with a frequency of BRCA1 mutations of >1% in the population based on DNA sequence

  2021cites this paper
• GBP5 Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy

  2021cites this paper
• Prognostic Role of Family History in Patients with Triple Negative Breast Cancer

  2020cites this paper
• PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice

  2020cites this paper
• Genetic polymorphisms and haplotypes of BRCA1 gene associated with quality of life and survival among patients with non-small-cell lung cancer

  2020cites this paper
• Switching the activity of Taq polymerase using clamp-like triplex aptamer structure

  2020cites this paper
• Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.

  2020cites this paper
• Effect of BRCA1 on the Concurrent Chemoradiotherapy Resistance of Cervical Squamous Cell Carcinoma Based on Transcriptome Sequencing Analysis

  2020cites this paper
• Relationship Between Xanthine Oxidoreductase Activity and BRCA1 Levels in Patients with Stage IIIA and IIIB Non-Small Cell Lung Cancer Being Treated with Neoadjuvant Chemotherapy

  2020cites this paper
• PARP-ингибиторы в лечении больных метастатическим раком молочной железы с герминальными мутациями в генах BRCA1/2. Опыт применения талазопариба в клинической практике

  2020cites this paper
• Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer

  2019cites this paper
• Epidemiology, Risk Factors, and Prevention

  2019cites this paper
• Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens

  2018influential citation
• Multiomics analysis on DNA methylation and the expression of both messenger RNA and microRNA in lung adenocarcinoma

  2018cites this paper
• Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

  2018cites this paper
• Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers

  2017cites this paper
• The Potentiality of BRCA as a Chemo-Predictor : A Literature Review

  2017cites this paper
• Medical Management of Breast Cancer in BRCA Mutation Carriers

  2017cites this paper
• Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC

  2016cites this paper
• Novel Candidate Biomarkers of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma: A Systematic Review

  2016cites this paper
• In silico Analysis of BRCA1 Gene and its Phylogenetic Relationship in some Selected Domestic Animal Species

  2016cites this paper
• Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus

  2016cites this paper
• Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer

  2016cites this paper
• Pharmacogenomics in the treatment of lung cancer: an update.

  2015cites this paper
• Epigenetics of Endocrine Tumors in Women and Dietary Prevention

  2015cites this paper
• Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.

  2015cites this paper
• Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.

  2015cites this paper
• The molecular and genetic basis of inherited cancer risk in gynaecology

  2015cites this paper
• Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I–III Non-Small Cell Lung Cancer

  2015cites this paper
• Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer

  2015cites this paper
• Epigenetics of BRCA-1–Related Breast Tumorigenesis and Dietary Prevention

  2014cites this paper
• O2-1-3GENE EXPRESSION SIGNATURE–BASED PROGNOSTIC RISK SCORE IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

  2014cites this paper
• Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy

  2014cites this paper
• Race differences in obesity and its relationship to the sex hormone milieu

  2014cites this paper
• THE ROLE OF GERMLINE BRCA1 FOUNDER MUTATIONS AND SOMATIC TP53 MUTATIONS IN THE TRIPLE-NEGATIVE BREAST CANCER SUBTYPE

  2014cites this paper
• Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer

  2013cites this paper
• Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC).

  2013cites this paper
• Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

  2013cites this paper
• Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non–small cell lung cancer

  2013cites this paper
• Expression of DNA-PKcs and BRCA1 as prognostic indicators in nasopharyngeal carcinoma following intensity-modulated radiation therapy

  2013cites this paper
• BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer

  2013cites this paper
• Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis

  2013cites this paper
• BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy

  2013cites this paper
• Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy

  2012cites this paper
• Tumour suppressor genes in chemotherapeutic drug response

  2012cites this paper
• Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle.

  2012cites this paper
• The potential of the PARP-1 inhibitor, AGO14699, in human cancers defective in homologous recombination DNA repair

  2012cites this paper
• ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer

  2012cites this paper
• BRCA1: a new candidate gene for bovine mastitis and its association analysis between single nucleotide polymorphisms and milk somatic cell score

  2012cites this paper
• Changes in the expression of plasma proteins associated with thrombosis in BRCA1 mutation carriers

  2012cites this paper
• BRCA1：一种新的非小细胞肺癌放化疗疗效的预测基因

  2012cites this paper
• Hexim‐1 modulates androgen receptor and the TGF‐β signaling during the progression of prostate cancer

  2012influential citation
• Gene Expression Signature–Based Prognostic Risk Score in Patients with Primary Central Nervous System Lymphoma

  2012cites this paper
• DNA repair genes BRCA1 and DNA-PKcs have great potential in radiation therapy

  2012cites this paper
• Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and &bgr; III-Tubulin in Thymic Epithelial Tumors

  2011cites this paper
• Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

  2011cites this paper
• Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

  2011cites this paper
• Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer

  2011cites this paper
• Hereditary Breast Cancer Syndromes

  2011cites this paper
• BRCA1 gene expression in relation to prognostic parameters of breast cancer

  2011cites this paper
• Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.

  2011cites this paper
• Inherited Cancer Syndromes

  2010influential citation
• Histologic diagnosis in young women with breast cancer

  2010cites this paper
• Prognostic and predictive factors in resected non-small-cell lung cancer.

  2010cites this paper
• Pathologic Complete Response Rates in Patients with BRCA1 Mutations: An Interesting and Evolving Story

  2010cites this paper
• Impact of biomarkers on non-small cell lung cancer treatment

  2010cites this paper
• Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer

  2010cites this paper
• Inhibition of RNA polymerase III transcription by BRCA1.

  2009cites this paper
• Hereditary ovarian cancer.

  2009cites this paper
• Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer.

  2009cites this paper
• BRCA1/2 predictive testing and gender: uptake, motivation and psychological characteristics.

  2009cites this paper
• Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

  2009cites this paper
• Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.

  2008cites this paper
• BRCA1: a new genomic marker for non-small-cell lung cancer.

  2008cites this paper
• Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy.

  2008cites this paper
• The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer

  2008cites this paper
• ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

  2008cites this paper
• GENOMIC AND TRANSCRIPTOME PROFILING OF EPITHELIAL OVARIAN CANCER

  2008cites this paper
• DNA Repair and Mitotic Checkpoint Genes as Potential Predictors of Chemotherapy Response in Non-Small-Cell Lung Cancer

  2008cites this paper
• Mechanisms of inherited cancer susceptibility

  2007cites this paper
• BRCA1, a potential predictive biomarker in the treatment of breast cancer.

  2007cites this paper
• The evolving role of chemotherapy in advanced urothelial cancer

  2007cites this paper
• Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer?

  2007cites this paper
• Immunolocalization of BRCA 1 protein in tumor breast tissue : prescreening of BRCA 1 mutation in Tunisian patients with hereditary breast cancer ?

  2007influential citation
• Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia

  2007cites this paper
• DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes.

  2006cites this paper
• Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

  2006cites this paper
• Nuevas perspectivas en el tratamiento del cáncer de pulmón no microcítico: farmacogenómica

  2006cites this paper